Skip to main content
. 2021 Jun 18;8:691611. doi: 10.3389/fcvm.2021.691611

Table 1.

Clinical and demographic characteristics at baseline.

All patients (n = 105) Patients who met the endpoint (n = 31) Patients who did not meet the endpoint (n = 74) p-value
Age (years) (median [IQR]) 54 [48–59.5] 58 [48–63] 54 [48–58] 0.123
Gender 0.79
      Female 21 (20) 7 (22.6) 14 (18.9)
      Male 84 (80) 24 (77.4) 60 (81.1)
Body mass index (kg/m2) 28.4 ± 4.6 28.3 ± 4.1 28.4 ± 4.8 0.96
Blood pressure (mmHg)
      Systolic 106.5 ± 18.1 97.7 ± 14.3 110.2 ± 18.3 0.001
      Diastolic 66.1 ± 12.5 60.5 ± 13.2 68.5 ± 11.5 0.002
NYHA class <0.0001
      NYHA II 45 (42.9) 3 (9.7) 42 (56.8)
      NYHA III 55 (52.4) 25 (80.6) 30 (40.5)
      NYHA IV 5 (4.8) 3 (9.7) 2 (2.7)
Etiology of HF 0.83
      DCM 63 (60) 18 (58.1) 45 (60.8)
      ICM 42 (40) 13 (41.9) 29 (39.2)
Peripheral Edema 16 (15.2) 10 (32.3) 6 (8.1) 0.005
HF known (months) (median [IQR]) 48 [15–122.5] 96 [36–144] 31.5 [11.3–96] 0.1
NT-proBNP, pg/dl (median [IQR]) 1,210 [435–3,696] 5,900 [4,053–9,076] 1,297 [589–3,544] <0.0001
Devices
      ICD 43 (41) 16 (51.6) 27 (36.5) 0.19
      CRT ± D 40 (38.1) 13 (41.9) 27 (36.5) 0.66
Bundle branch block
      LBBB 14 (13.3) 6 (19.4) 8 (10.8) 0.34
      BBB caused by pacemaker 36 (34.3) 13 (41.9) 23 (31.1) 0.37
Medication
      Beta-blocker 98 (93.3) 27 (87.1) 71 (95.9) 0.19
      ACE-I 20 (19) 4 (12.9) 16 (21.6) 0.42
      ARB 13 (12.4) 4 (12.9) 8 (12.2) 1.0
      ARNI 71 (67.6) 21 (67.7) 50 (67.6) 1.0
      Aldosterone antagonist 90 (85.7) 25 (80.6) 65 (87.8) 0.37
      Loop diuretic 90 (85.7) 30 (96.8) 60 (81.1) 0.037
Cardiopulmonary test
      VO2 peak, ml/min/kg 11.9 ± 5.0 9.1 ± 2.6 13.2 ± 5.3 <0.0001
VE/VCO2 slope, l/l (median [IQR]) 34 [29–41] 41 [36–46.5] 31 [28–37] <0.0001

Values are given as a number (percent) or mean ± standard deviation except where otherwise indicated.

IQR, interquartile range; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; ICM, heart failure caused by ischemic heart disease; BNP, brain natriuretic peptide, ICD, implantable cardioverter-defibrillator; CRT ± D, cardiac resynchronization therapy with or without defibrillator; LBBB, left bundle branch block; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin-receptor neprilysin inhibitor; peak VO2, peak oxygen uptake; VE/VCO2, ventilation-carbon dioxide output relation.